Amedisys (AMED) Receiving Somewhat Positive Media Coverage, Analysis Shows
Headlines about Amedisys (NASDAQ:AMED) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amedisys earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the health services provider an impact score of 45.6592417625791 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Amedisys (AMED) traded up 1.41% during midday trading on Monday, reaching $52.58. 110,414 shares of the company’s stock traded hands. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91. The stock has a market cap of $1.78 billion, a P/E ratio of 44.94 and a beta of 0.84. The company’s 50-day moving average price is $50.08 and its 200-day moving average price is $54.82.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. Amedisys’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.42 EPS. On average, equities analysts predict that Amedisys will post $2.21 EPS for the current fiscal year.
A number of brokerages recently weighed in on AMED. Mizuho downgraded shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research note on Wednesday, July 26th. Bank of America Corporation began coverage on shares of Amedisys in a research note on Monday, August 21st. They set a “neutral” rating and a $55.00 target price for the company. BidaskClub raised shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $56.00 target price on shares of Amedisys in a research note on Monday, June 5th. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $56.33.
ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/11/amedisys-amed-receiving-somewhat-positive-media-coverage-analysis-shows.html.
In other Amedisys news, Director Bruce D. Perkins purchased 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was bought at an average cost of $46.60 per share, for a total transaction of $93,200.00. Following the purchase, the director now directly owns 15,825 shares in the company, valued at $737,445. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares of the company’s stock, valued at $524,400. The disclosure for this sale can be found here. 2.80% of the stock is owned by company insiders.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.